GL1X · GenesisL1 explorer

Research workbench

Discovery of potent orally bioavailable wd repeat domain 5 (WDR5) inhibitors using a pharmacophore-based optimization

Analyse Discovery of potent orally bioavailable wd repeat domain 5 (WDR5) inhibitors… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
7UAS
Type
protein
Length
606 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Wd repeat-containing protein 5
UniProt
P61964
Ligands
MBU
Pockets
3 · best druggability 0.83

Structure

x-ray diffraction · 2 distinct chains · 0% helix, 53% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AWd repeat-containing protein 5protein3020% helix, 53% strandP61964
BWd repeat-containing protein 5protein3040% helix, 53% strandP61964

Ligands and binding sites

  • MBU · (5P)-2-[(S)-cyclopropyl(4-methylpyridin-2-yl)methyl]-5-[1-ethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-7-[(2-methyl-1H-imidazol-1-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
110960.830.8496MBU
26760.750.8166MBU
31500.500.7928empty

Interfaces

1 interface between chains.

  • A–B · 466 Ų buried · 2 hydrogen bonds · protein-protein

Compared structures

  • 7UAS · Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a… · the same entry in another collection · chain B against B, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.